---
title: Acid sphingomyelinase activity suggests a new antipsychotic pharmaco-treatment
  strategy for schizophrenia
date: '2025-01-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39825014/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250118170356&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Schizophrenia is a chronic and severe mental disorder. It is currently
  treated with antipsychotic drugs (APD). However, APD's work only in a limited number
  of patients and may have cognition impairing side effects. A growing body of evidence
  points out the potential involvement of abnormal sphingolipid metabolism in the
  pathophysiology of schizophrenia. Here, an analysis of human gene polymorphisms
  and brain gene expression in schizophrenia patients identified an association of
  SMPD1 and ...
disable_comments: true
---
Schizophrenia is a chronic and severe mental disorder. It is currently treated with antipsychotic drugs (APD). However, APD's work only in a limited number of patients and may have cognition impairing side effects. A growing body of evidence points out the potential involvement of abnormal sphingolipid metabolism in the pathophysiology of schizophrenia. Here, an analysis of human gene polymorphisms and brain gene expression in schizophrenia patients identified an association of SMPD1 and ...